Avacta Group Plc develops cancer drugs and in vitro diagnostics in the United Kingdom, France, North America, South Korea, rest of Europe, and internationally. The company operates through Diagnostics and Therapeutics segments. It provides its proprietary Affimer and pre|CISION technology platforms, which is used to deliver a portfolio of differentiated th therapeutic and diagnostic products that addresses various markets. The company develops AVA6000, a peptide drug conjugate form of doxorubicin that is in Phase I clinical trial to treat locally advanced or metastatic solid tumour; AVA3996, a tumor-activated proteasome inhibitor based on Velcade; and AVA032, a bispecific molecule which is in pre-clinical trials that regulates the activation and proliferation of immune cells. It develops AVA-028-PD-L1 Affimer/ImmunoCytokines; AVA-021 - PD-L1 Affimer/LAG-3 Affimer; and TMAC platform that utilizes the proprietary pre|CISION substrate to provide for the selective release of a drug moiety by FAPa. The company has a collaboration agreement with LG Chem for developing and commercializing Affimer based therapeutics. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.
| 0.9076 | |
| 0.9076 | |
| - | |
| 0.9076 | |
| 0.9076 | |
| 0.4786-2.17 | |
| 324 M | |
| 356 M | |
| 23 247 K | |
| -0.0283 | |
| 1.146 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
For us, stock picking is in large part the hunt for the truly magnificent stocks. But when you hold the right stock for the right time period, the rewards can be truly huge. For example, the Avacta Gr...
If you want to know who really controls Avacta Group Plc (LON:AVCT), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, around 58...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
